2022 年第 1 期 第 17 卷

钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病合并高血压患者中应用的研究进展

Research pogress of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus complicated with hypertension

作者：张涛1邵清淼2

英文作者：Zhang Tao1 Shao Qingmiao2

单位：1天津中医药大学第一附属医院肾病科国家中医针灸临床医学研究中心，天津300380；2天津市心血管病离子与分子机能重点实验室天津医科大学第二医院心脏科天津心脏病学研究所，天津300211

英文单位：1Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese Medicine National Clinical Research Center for Chinese Medicine Acuquncture and Moxibustion Tianjin 300380 China; 2Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease Department of Cardiology the Second Hospital of Tianjin Medical University Tianjin Institute of Cardiology Tianjin 300211 China

关键词：2型糖尿病；钠-葡萄糖协同转运蛋白2抑制剂；高血压

英文关键词：Type2diabetesmellitus;Sodium-glucosecotransporter-2inhibitors;Hypertension

• 摘要：

• 近年来糖尿病发病率显著升高，尤其是2型糖尿病（T2DM）。T2DM与高血压的发生发展密切相关，T2DM合并高血压可对患者心、脑、肾等靶器官造成损害。因此，合理有效地控制T2DM患者的血压水平至关重要。钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂作为一种新型降糖药，除具有降糖作用外，还具有心、肾保护等作用。本文对SGLT-2抑制剂在T2DM合并高血压患者中的降压效果和安全性及其潜在降压机制进行综述。

• In recent years, the morbidity of diabetes mellitus has increased significantly, especially in type 2 diabetes mellitus (T2DM). T2DM is closely related to the occurrence and development of hypertension, and causes damage to target organs such as heart, brain and kidney. Therefore, the reasonable and effective control of blood pressure in patients with T2DM is very important. The sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as a new type of hypoglycemic drug, not only has the hypoglycemic effect, but also has other function such as protecting heart and kidney. In this paper, the antihypertensive effect and safety of SGLT-2 inhibitors on T2DM patients with hypertension and their potential antihypertensive mechanisms are reviewed.